Affiliation:
1. Department of Haematology Gloucestershire Hospitals NHS Foundation Trust Gloucester UK
Abstract
In a large multicentre retrospective real‐world analysis, Hess and colleagues describe outcomes in post‐Bruton tyrosine kinase inhibitor (BTKi) mantle cell lymphoma patients managed in clinical practice prior to availability of brexucabtagene autoleucel (Tecartus). Outcome data not only provide a useful benchmark for future studies but also highlight the great challenges that still lie ahead in managing this challenging patient cohort.Commentary on: Hess et al. Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart review study. Br J Haematol 2023;202:749–759.